Cellectar Biosciences Inc’s recent filing unveils that its Chief Operating Officer Longcor Jarrod acquired Company’s shares for reported $8400.0 on Jan 10 ’25. In the deal valued at $0.28 per share,30,000 shares were bought. As a result of this transaction, Longcor Jarrod now holds 83,141 shares worth roughly $21616.66.
A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early July with a ‘”an Outperform”‘ rating. ROTH Capital started covering the stock on September 13, 2019. It rated CLRB as “a Buy”.
Price Performance Review of CLRB
On Friday, Cellectar Biosciences Inc [NASDAQ:CLRB] saw its stock fall -9.82% to $0.26. Over the last five days, the stock has lost -21.03%. Cellectar Biosciences Inc shares have fallen nearly -11.57% since the year began. Nevertheless, the stocks have fallen -93.36% over the past one year. While a 52-week high of $4.15 was reached on 03/20/25, a 52-week low of $0.22 was recorded on 01/15/25. SMA at 50 days reached $0.3055, while 200 days put it at $1.4008.
Levels Of Support And Resistance For CLRB Stock
The 24-hour chart illustrates a support level at 0.2328, which if violated will result in even more drops to 0.2011. On the upside, there is a resistance level at 0.2947. A further resistance level may holdings at 0.3249. The Relative Strength Index (RSI) on the 14-day chart is 34.54, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0578, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 81.02%. Stochastics %K at 13.84% indicates the stock is a buying.
How much short interest is there in Cellectar Biosciences Inc?
A steep rise in short interest was recorded in Cellectar Biosciences Inc stocks on 2025-03-14, growing by 0.59 million shares to a total of 2.92 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 2.34 million shares. There was a rise of 20.04%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 21, 2016 when Ladenburg Thalmann began covering the stock and recommended ‘”a Buy”‘ rating along with a $2.70 price target.
